Table 1.

Effects of MA-33B8 and MA-56A7C10 on the outcome of IPFT with 0.25 mg/kg scuPA and on the levels of active PAI-1 and αM/uPA complexes in the pleural fluids at 24 h after IPFT

				Pleural Fluids at 24 h
scuPA Treatment, mg/kg	Adjunct	Adjunct Dose, mg/kg	Outcome (GLIS)*	PAI-1, nM†	αM/uPA, nM
0.25	Mouse IgG	0.5	17	2.4 ± 0.6	0.45 ± 0.08
0.25	MA-33B8	0.5	3	2.1 ± 0.4	1.6 ± 0.6
0.25	MA-56A7C10	0.5	50	6.7 ± 0.9	0.34 ± 0.07
0	Mouse IgG	0.5	50	3.2 ± 0.4	<0.02

Levels of active PAI-1 and αM/uPA complexes are means ± SE; n = 2 for each group. IPFT, intrapleural fibrinolytic therapy; scuPA, prourokinase; αM, α-macroglobulin; uPA, urokinase.

^*Gross lung injury score (GLIS; 25, 48) was determined by counting number of strands, webs, and aggregates of intrapleural fibrin organizations to quantify the extent of the injury. GLIS from 0 to 10 and from 11 to 50 correspond to successful or unsuccessful IPFT, respectively. The differences in median values among the treatment groups were statistically significant (P = 0.025).

^†Plasminogen activator inhibitor-1 (PAI-1) activity was estimated from the results of inhibition of exogenous two-chain uPA (tcuPA; 0.5 nM), added to the samples of pleural fluids as previously described.